Abstract:Objective: The objective of this study was to design a virtual screening (VS) protocol for identifying potential fibroblast growth factor receptor 4 (FGFR4) inhibitors from the commercially available Specs database. This was based on an experimental model of FGFR4 bound to the potent inhibitor FGF401 (PDB: 7VJL), with the aim of discovering novel compounds with therapeutic potential for various tumor types. Methods: The study comprised two main parts. Firstly, a ligand-based pharmacophore model was constructed using known potent FGFR4 inhibitors to discriminate between actives and decoys. Secondly, docking studies of the identified actives were conducted within the binding pocket of the FGFR4 experimental model. This aimed to assess the ability of the compounds to overlay on the reference inhibitor and interact similarly within the binding site. The virtual screening protocol was then applied to the Specs database to identify potential FGFR4 inhibitors. Results: The ligand-based pharmacophore model exhibited promising discrimination capabilities, achieving a true positive percentage of 100% and a false positive percentage of 7%. Docking studies revealed that the selected compounds overlaid well with the reference inhibitor and exhibited interactions within the FGFR4 binding pocket. Through the virtual screening of the Specs database, compound A emerged as the most suitable candidate. Molecular dynamics simulation and Molecular Mechanics Poisson-Boltzmann Surface Area (MMPBSA) calculations further supported the efficacy of compound A as a FGFR4 inhibitor. Additionally, compound A demonstrated favorable absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties, along with adherence to Lipinski’s rule of 5, enhancing its potential as a lead compound. Conclusion: In conclusion, compound A emerged as a promising selective FGFR4 inhibitor with potential for therapeutic use in various cancers. Further in vitro experiments and animal cancer model studies are warranted to validate its efficacy. The study highlights the effectiveness of the proposed virtual screening protocol in identifying novel FGFR4 inhibitors, offering a promising avenue for future drug discovery efforts in oncology.

Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles.

Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles

Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4

Structure-based design of a dual-warhead covalent inhibitor of FGFR4

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors

Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer

Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors

Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma

Design, Synthesis, and Biological Evaluation of Quinazoline Derivatives with Covalent Reversible Warheads As Potential FGFR4 Inhibitors

Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants

Virtual Screening, Molecular Dynamics, MM-PBSA and In-silico Studies in Search of Potent Novel Fibroblast Growth Factor Receptors 4 Inhibitor

Discovery of 1,6-Naphthyridin-2(1 H )-one Derivatives as Novel, Potent, and Selective FGFR4 Inhibitors for the Treatment of Hepatocellular Carcinoma

Discovery of novel FGFR4 inhibitors through a build-up fragment strategy

Discovery of Novel 7-Azaindole Derivatives As Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma